Clinical trials: Major Depressive Disorder Remission, open to volunteers
Major Depressive Disorder (MDD)
Predictors of Relapse in Major Depressive Disorder (PERFORM-D)
Major depressive disorder (MDD) is a common condition involving recurring periods of depression. One of the major challenges faced by people with MDD is that the episodes of depression tend to recur even after they are…
- Trial name
- PERFORM-D (NCT06746155)
- Where
- 9 sites in Canada
- Volunteers
- 252 people
- Sponsor
- Abraham Nunes
Major Depressive Disorder, Recurrent, in Remission, Major Depressive Disorder, Recurrent, Mild
Mindfulness-Based Cognitive Therapy (MBCT) for the Prevention of Depression Relapse or Recurrence Using Videoconference
Objectives: To evaluate the clinical- and cost-effectiveness of two delivery formats of mindfulness-based cognitive therapy (MBCT) - (i) MBCT delivered through eight videoconference group sessions (group MBCT), and (ii) MBCT…
- Conditions
- Major Depressive Disorder, Recurrent, in Remission, Major Depressive Disorder, Recurrent, Mild, Major Depressive Disorder, Recurrent, Moderate
- Trial name
- BECOME (NCT06832605)
- Testing
- Group Mindfulness-Based Cognitive Therapy, Mindfulness-Based Cognitive Therapy Self-Help, Treatment as Usual (TAU)
- Where
- 5 sites in Spain
- Volunteers
- 342 people
- Sponsor
- Fundació Sant Joan de Déu
Major Depressive Disorder, Recurrent, in Remission
Light and Ion Maintenance In Treatment for Depression (LIMIT-D): Feasibility Study
Antidepressants are widely used as first-line treatments for major depressive disorder (MDD). Clinical guidelines recommend 6-24 months of "maintenance" antidepressant treatment, after patients achieve symptom remission, to…
- Trial name
- NCT05423275
- Testing
- Negative ion therapy, Light therapy
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University of British Columbia
Adjunct in the Treatment of Depressive Disorder
A Randomized, 52-Week Extension Study to Evaluate the Maintenance of Remission, Relapse Prevention, and Long-Term Safety of CreNeuroS™ in Patients With Major Depressive Disorder Who Achieved Remission Following an 8-Week Parent Study
This multicenter, randomized, open-label extension study will evaluate the maintenance of remission, relapse prevention, long-term clinical outcomes, and safety of CreNeuroS™ in participants with Major Depressive Disorder (MDD)…
- Trial name
- NCT07893002
- Testing
- No intervention, CreNeuroS™ CNS Fish Oil Plus Softgels, 1 capsule orally once daily, CreNeuroS™ CNS Fish Oil Plus Softgels, 2 capsule orally once daily
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Sichuan Credit Pharmaceutical Co., Ltd.